Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia.

Magdalena WitkowskaAgata MajchrzakPaweł Robak Anna Wolska-Washer Tadeusz Robak

Published in: Expert opinion on drug metabolism & toxicology (2023)

The development of novel PI3Kδ inhibitors might help to reduce toxicity and improve efficacy in patients with CLL and other B-cell lymphoid malignancies.

Keyphrases

chronic lymphocytic leukemia
oxidative stress
protein kinase
tyrosine kinase
replacement therapy
smoking cessation